Background: Individuals presenting for care with severe immunosuppression typically have high plasma HIV viral load (pVL) and may transmit HIV before and after initiation of combination antiretroviral therapies (cART).
Introduction
Early initiation of effective combination antiretroviral therapies (cART) dramatically improves the prognosis of HIV-infected patients and, by suppressing plasma HIV viral load (pVL), markedly reduces sexual transmission of HIV. [1] [2] [3] [4] However, despite cART success, late presentation for HIV care remains common in most settings, 5, 6 including high-income countries. 6 More than 30% of patients presenting for care in Europe have advanced HIV disease, defined as CD4 counts ,200 cells/mm 3 or AIDS-defining disease. 6 Advanced stage of infection is typically accompanied by high pVL, which requires a longer time to achieve viral suppression following cART initiation. 7, 8 Thus, persons presenting for care with severe immunosuppression may be at high risk of transmitting HIV before and after cART initiation, as high pVL implies high risk of sexual HIV transmission. 9 Recent studies in low-and middle-income countries have shown that HIV transmission risk persists during the first 6 months of cART. 2, 10 However, little is known about the risk of HIV transmission before, and after, cART initiation for individuals presenting for care with severe immunosuppression, notably in high-income countries. Quantifying these risks is critical for HIV-infected patients and their partners, as well as for clinicians and healthcare policymakers seeking to implement interventions aimed at reducing the risk of onward HIV transmission and accelerating care entry. Here, we used virological and behavioural data collected within the framework of the IMEA 040 DATA trial 11 to quantify, for individuals presenting for care with severe immunosuppression, the risk of HIV transmission before and within the first 48 weeks of cART initiation.
Methods

Study population
The IMEA 040 DATA trial has been described previously. 11 Between April 2011 and January 2013, 120 patients were enrolled into an open-label, non-comparative, randomized, multicentre trial to evaluate the efficacy and tolerability of atazanavir/ritonavir or darunavir/ritonavir as first-line therapy, each in combination with two nucleos(t)ide reverse transcriptase inhibitors. Levels of pVL and CD4 cell counts were assessed at treatment initiation, defined as week (W) 0, and weeks 2, 4, 12, 24, 36 and 48 . In addition to assessing the efficacy of cART regimens, an ancillary study was conducted to collect information on sexual behaviours at W0, W24 and W48, using self-reported questionnaires (the questionnaire is available as Supplementary data at JAC Online) based on 4 week recall. Questions covered sexual activity and condomless sex with main, regular and casual partners as well as partner's HIV status (positive/negative/unknown).
Ethics
The trial respected good clinical practices and the ethical principles of the Declaration of Helsinki. The Ile de France XI ethics review committee approved the study (number 10062) and all the patients gave their written informed consent before participation. The study was registered with ClinicalTrials.gov (NCT01928407).
Analysis
To assess HIV transmission risk before and after cART initiation we evaluated two measures for each patient (i.e. trial participant) who participated in the ancillary study: the per-act risk of HIV transmission and the monthly rate of HIV transmission. Note that we could not ascertain whether HIV seroconversions occurred among partners of trial participants as only trial participants (and not their partners) were followed up during this study. The per-act risk of HIV transmission was estimated for each patient using the dose-response relationship between pVL and risk of HIV transmission, 9 whether or not the patient reported any sexual activity. The per-act probability of HIV transmission was shown to increase by a factor of 2.45 (95% CI 1.85-3.26) for each log 10 increment in pVL, as expressed by the following equation: 
where V 0 is the average pVL during untreated chronic HIV infection, b 0 is the per-act probability of HIV transmission from a person with pVL V 0 , and b 1 is the per-act transmission probability corresponding to pVL V 1 . We assumed that V 0 was 4.5 log 10 copies/mL, 12 and b 0 was equal to 0.001 for heterosexuals 13 and 0.01 for MSM. 12 Regarding the parameter determining the increase in transmission probability, with each 1 log increment in pVL, each individual was assigned a value sampled from a normal distribution with mean 2.45 and standard deviation (SD) 0.35, corresponding to the 95% CI. The risk of HIV transmission was neglected for undetectable pVL, defined as plasma HIV-RNA concentrations ,50 copies/mL. 2 We combined virological and behavioural data to quantify, for each patient, the monthly rate of HIV transmission using the formula:
where C M , C R and C C are the monthly rates of HIV transmission to HIVnegative main, regular and casual partners, respectively. Monthly rates for each kind of partnership were calculated using the binomial formula:
where e is the per-act condom efficacy, n is the number of sex acts over the previous 4 weeks, and k is the number of sex acts protected by condom over the previous 4 weeks. We assumed that the per-act condom efficacy was 75% (95% CI 63%-83%), 13 and thus we assigned a per-act condom efficacy value to each individual, that was sampled from a normal distribution with mean 0.75 and SD 0.05, corresponding to the 95% CI. Partners of unknown status were assumed to be HIV-negative.
We performed sensitivity analyses where we assumed that the per-act risk of HIV transmission during each act of sexual intercourse was reduced by 95% for all patients. This analysis corresponds to an optimistic scenario where all couples would consistently and correctly use prevention, i.e. condoms 14 or pre-exposure prophylaxis (PrEP), 15, 16 to reduce the risk of HIV transmission. Then we compared estimates obtained under this scenario with those in the baseline analysis to estimate the percentage reduction in the monthly rates of HIV transmission within the optimistic scenario.
Analyses were conducted using Matlab R2015b and IBM SPSS Statistics version 24. As viral decay dynamics were similar for the two first-line therapies (atazanavir/ritonavir versus darunavir/ritonavir), we did not stratify the analysis according to the therapy. Generalized estimating equations models were used to analyse changes in parameters over time.
Results
Eighty-four patients participated in the survey and completed at least one of the three questionnaires. Among participants, 56% were heterosexual (24 male, 23 female) and 44% MSM (Table 1) . Median time from HIV diagnosis to cART initiation was 4 weeks. At cART initiation (W0), median CD4 cell count was 71 cells/mm 3 and median pVL was 5.4 log 10 for heterosexuals, and, respectively, 89 cells/mm 3 and 5.2 log 10 for MSM. Using data on pVL at W0, we estimated that the median per-act risk of HIV transmission at cART initiation was more than seven times Figure 1a and b]. The percentage of patients with unsuppressed viral load (pVL .50 copies/mL) decreased from 100% at cART initiation to 78% (95% CI 64%-89%) at W12, 38% (95% CI 25%-54%) at W24, and 27% (95% CI 16%-43%) at W48 for heterosexuals (P , 0.001), and, respectively, 73% (95% CI 56%-86%), 33% (95% CI 18%-50%) and 8% (95% CI 2%-22%) for MSM (P , 0.001). Among those who remained virologically unsuppressed, pVL considerably declined within the first 12 weeks of cART-median pVL was 2.3 log 10 (IQR 2.1-2.5) for heterosexuals and 2.2 log 10 (IQR 1.9-2.5) for MSM at W12-and then remained relatively stable (data not shown). This translated into a reduction of the per-act risk of HIV transmission for virologically unsuppressed individuals, with estimated median values, at W12, of 0.0001 (IQR 0.0001-0.0002) for heterosexuals (P , 0.001 versus W0, Figure 1a ) and 0.0010 (IQR 0.0000-0.0017) for MSM (P , 0.001 versus W0, Figure 1b) , and mean reductions, when compared with W0, of 90% (95% CI 86%-94%) for heterosexuals and 92% (95% CI 91%-94%) for MSM.
The sexual behaviour of patients before and after cART initiation is summarized in Table 2 . Over the course of treatment, the percentage of patients reporting sex with HIV-negative or unknown serostatus (HNUS) partners increased, from 23% (95% CI 10%-42%) at cART initiation to 42% (95% CI 25%-61%) at W48 for heterosexuals (P " 0.042) and, respectively, from 41% (95% CI 21%-64%) to 73% (95% CI 52%-88%) for MSM (P " 0.004). Among patients reporting sex with HNUS partners, the percentage of those who reported condomless sex decreased from 43% (95% CI 10%-82%) at cART initiation to 14% (95% CI 2%-43%) at W48 for heterosexuals (P " 0.124) and, respectively, from 56% (95% CI 21%-86%) to 32% (95% CI 13%-57%) for MSM (P " 0.224).
By combining virological and behavioural data, we found that during the month before treatment, 23% (95% CI 10%-42%) of heterosexuals ( Figure 1c ) and 41% (95% CI 21%-64%) of MSM ( Figure 1d ) were virologically unsuppressed and had sex with HNUS partners. Among these patients, the estimated median monthly rate of HIV transmission was almost 30 times higher for MSM than for heterosexuals, 0.0540 (IQR 0.0339-0.0742) versus Supervie et al.
0.0018 (IQR 0.0014-0.0191) (P " 0.008) (Figure 1c and d) . Over the course of cART, the percentage of HIV-infected patients who remained virologically unsuppressed and had sex with HNUS partners decreased to 16% (95% CI 5%-33%) (P " 0.291) at W24 and 9% (95% CI 2%-24%) (P " 0.109) at W48 for heterosexuals and, respectively, 25% (95% CI 11%-45%) (P " 0.234) and 4% (95% CI 0%-20%) (P " 0.010) for MSM. Estimated median monthly rates of HIV transmission for these patients decreased to 0.0001 (IQR 0.0001-0.0006) for heterosexuals (P " 0.053) and 0.0024 (IQR 0.0017-0.0038) for MSM (P , 0.001) at W24 and then remained stable, corresponding to mean reductions, relative to W0, of 95% (87%-100%) for heterosexuals and 98% (95%-100%) for MSM. Under an optimistic scenario, i.e. assuming that the per-act risk of HIV transmission during each act of sexual intercourse reduced by 95% for all patients, the estimated median monthly rate of HIV transmission, among patients who were virologically unsuppressed and had sex with HNUS partners, was 0.0003 (IQR 0.0002-0.0010) for heterosexuals and 0.0049 (IQR 0.0037-0.0072) for MSM at cART initiation (P " 0.016). This rate decreased to 0.00003 (IQR 0.00003-0.00013) for heterosexuals (P " 0.205) and 0.0004 (IQR 0.0002-0.0005) for MSM (P , 0.001) at W24 and then remained stable. Thus, under the optimistic scenario, the monthly rate of HIV transmission at cART initiation was reduced by 93% (85%-100%) for heterosexuals and 98% (95%-100%) for MSM at W24, compared with the baseline analysis.
Discussion
With an estimated median value of 5%, we found that the monthly rate of HIV transmission before cART initiation was particularly high for MSM-30 times higher than for heterosexualsreflecting higher self-reported sexual activity for MSM than heterosexuals but, above all, higher per-act risk of HIV transmission for MSM than heterosexuals. Indeed, taken alone, the higher sexual activity for MSM compared with heterosexuals serves to increase the median value of the monthly rate of HIV transmission by a factor of 3, while the higher per-act risk of HIV transmission for MSM compared with heterosexuals serves to increase this median value by a factor of 10 (results not shown). Although sexual activity increased after cART initiation, and more than a third of individuals remained virologically unsuppressed (pVL .50 copies/mL) after 24 weeks of cART, the risk of HIV transmission significantly decreased, as early as 12 weeks of cART, and by $95% after 24 weeks of cART, even for those who remained virologically unsuppressed. In addition, we found that the monthly rate of HIV transmission before and after cART initiation could be significantly decreased (from 93% to 98%) if all patients or their partners would use consistently and correctly an HIV prevention method, i.e. condoms 14 or PrEP. 15, 16 The main limitation of our study is the sample size. In addition, our estimates of the risk of HIV transmission before cART initiation may have limited application for patients at less advanced stages of HIV infection, when pVL is usually lower, or for undiagnosed HIV infections, when sexual activity may be higher. The main strength of our study is the collection at regular and close time intervals of detailed behavioural and virological data, to inform and reinforce public health policies.
Our findings show a high risk of onward transmission before and during the first weeks of cART initiation for individuals presenting for care with severe immunosuppression, and persistence of a risk of HIV transmission, though at a substantially reduced level, beyond 24 weeks of cART for some individuals. Hence, our study enforces the need to implement effective HIV testing strategies, with a focus on individuals with low HIV testing uptake, and cART initiation as soon as possible. Furthermore, at cART initiation, communicating about this risk and providing counselling on how to reduce this risk, e.g. by improving condom use or offering PrEP to HIV-negative partners, is essential to reduce the risk of onward transmission until full viral suppression has been achieved. Partner notification assistance programmes, which are not implemented in France, should also be evaluated. This could allow earlier HIV diagnosis for partners of newly diagnosed HIV cases and provide an opportunity to offer PrEP to HIV-negative partners in serodiscordant couples until the HIV-positive partner achieves full viral suppression. In addition, investigating whether faster viral suppression could be achieved for severely immunosuppressed individuals using new drugs, such as integrase inhibitors, is important to reduce the risk of onward transmission after cART initiation.
